Key Takeaways
- Paste PVC drags, Suspension PVC lifts: Standalone EBITDA was weighed down by soft Paste PVC prices and margins from EU dumping, while Suspension PVC margins improved QoQ and YoY, driving the overall recovery.
- CMCD stays on the ₹1,000 crore path but ramp-up slows: 17 products commercialized and Phase 3/4 civil works progressing, yet newly launched ag-chem molecules face a couple of quarters' deferment as innovator offtake slows under Chinese price pressure.
- ADD and QCO outcomes are binary, imminent risks: Suspension PVC ADD final findings were gazetted 17 August with a confused deadline; if it lapses, management warns of a flood of low-quality Chinese imports and 2–3 quarters of challenge. The BIS quality order on PVC was revoked, a setback for public health norms.
- Refrigerant gas build-out begins, quota clarity is years away: A swing R32 plant converts existing R22 capacity within a month; two more small plants follow by April, but the 10 kt plant has no timeline and quota allocation rules will not be known until ~2027.
- What to watch next quarter: Whether Suspension PVC ADD is implemented or lapses, the pace of Paste PVC margin recovery if EU dumping is checked, and any firming of CMCD molecule offtake schedules.
PVC: The ADD Cliff and the Paste PVC Squeeze
- Suspension PVC ADD hangs in the balance: Final findings were recommended 14 August and gazetted 17 August, but confusion over which date triggers the deadline leaves the duty's fate uncertain. Management warns that if ADD lapses, it would be detrimental to domestic industry, downstream consumers and non-Chinese exporters, and could open floodgates for low-quality, substandard, unfairly priced Chinese imports.
- Without ADD, a multi-quarter challenge: If the duty is not implemented, the company expects at least 2–3 quarters of challenge before organic PVC cycle improvement and better prices and margins can offset the hit.
- The application covered all major dumpers: The October 2023 ADD filing named China (~54% of imports), Japan (~14%), Taiwan (~10%) and others; the final word is still awaited.
- BIS quality order revoked: The Quality Control Order on PVC resin, which would have enforced a residual VCM limit of 1 ppm for drinking-water pipe applications, had its implementation extended to ~23 December and has now been revoked entirely, a setback management frames as a public health and safety issue.
- Paste PVC: demand recovers, margins don't: Domestic demand strengthened in Q2, led by automotive and footwear, and the new Cuddalore plant ran at full capacity. But margins stayed soft because low-priced imports, especially from EU-based suppliers, continued to undercut prices.
- EU dumping fills the China void: After ADD was imposed on China and a few other countries earlier this year, dumping increased from European Union producers. A new anti-dumping petition against EU producers is well underway. Management believes European producers cross-subsidize exports by keeping domestic prices high, which is exactly what the petition targets.
- One European plant shut, more rationalization possible: A ~230,000 tonne PVC plant in Europe has shut down, and other chlorovinyl assets are being rationalized. EU total capacity is ~0.7–0.75 crore tonnes but not all plants run at full operating rates.
- China anti-involution is still talk: Management sees no action on the ground yet from China's anti-involution campaign; how much capacity gets shut down and in what timeframe remains unclear.
- India is structurally short PVC: Last year's demand was 0.43 crore tonnes against domestic production of 0.15 crore tonnes, so India is not a net exporter and domestic capacity additions remain critical.
Ramkumar Shankar: "If the ADD is allowed to elapse or it does not become effective, we believe that it will be detrimental to the country's interest on many grounds because it is absolutely crucial that we should have it."
Custom Manufactured Chemicals: On Track, With a Couple of Quarters' Slack
- Revenue guidance held at ₹1,000 crores by FY27: Management reaffirmed the target and remains confident in long-term projections, citing a strong pipeline and very active customer engagement.
- But ramp-up is slowing on newly launched molecules: The global ag-chem market shows stable demand but significant ongoing price pressure from Chinese capacity overhang. Innovator companies are deferring offtake of newly launched molecules, and many projects commercialized in the last 18 months fall into that category, so ramp-up could slip by a couple of quarters.
- 17 products commercialized, more in the pipeline: Three molecules commercialized so far this year, with one more anticipated in Q4. Phase 3 of MPB 3 and civil works for MPB 4 are progressing well.
- Margin target: 20–25% EBITDA at maturity: Currently slightly lower, but management sees CMO companies continuing to operate at good levels because pricing pressure has been on generics, not on custom manufacturing.
- Self-sustaining by FY27–28: At ₹1,000–₹1,200 crores of revenue, the CMCD business is expected to become self-sustaining in operating cash flow, funding all future capex. Future capex will mostly stay at the Berigai site unless customers require a second site, for which an alternate location is already identified.
Krishna Rangachari: "A lot of the pressure with respect to pricing has been on generics. So the ag-chem generic companies have been struggling because of the China prices. So I don't see the custom manufacturing business itself having significant pressure."
Refrigerant Gas: Building Capacity Before the Rules Are Written
- Swing plant ready within a month: Work has started on converting the existing R22 plant at Mettur into a swing R32 plant; the first 2 kt should be ready by 1 January. A second 2 kt plant follows by around April. Both are planned to run at optimal utilization throughout 2026.
- A larger 10 kt plant is planned but unscheduled: Management disclosed the capex (₹250 crores) but gave no timeline for construction. A decision on that plant is expected before end-December.
- Quota clarity is ~2027, creating a multi-year uncertainty: R32 quota allocation rules will be determined only by around calendar 2027. Management believes quotas should be allocated based on capacities available on the ground in the sequence they come up, and that India needs R32 capacity for air-conditioning demand, but acknowledged they do not have clarity on what eligibility they would get if they ramp up in CY26.
Value-Added Chemicals and Suspension PVC: Mixed Volume Signals
- Value-added chemicals volumes fell 15% YoY: Lower caustic production from temporary plant operational issues and conscious make-or-buy decisions drove the decline, which in turn reduced hydrogen peroxide volumes. Caustic soda demand stayed stable across key sectors but prices declined marginally. Chloromethane saw higher sales volumes with steady pricing.
- Suspension PVC volumes rose 11% YoY despite a monsoon-softened quarter: Pricing was volatile, rising in July and August but correcting thereafter. Chinese and US suppliers continue to exert downward pressure on prices due to surplus capacity and weak global demand, leading to further stress on prices and margins in October.
- PVC spreads remain tight: Chinese PVC at $650 and VCM at ~$500 put the PVC-minus-VCM spread in a narrow range, with various other add-ons and offsets.
Balance Sheet and Capex: The Heavy Lifting Is Done
- Major capex is behind the company: Paste PVC is running at over 100% utilization. The only significant remaining capex is the R32 build-out. Management believes the debt level has peaked and gearing will come down in coming quarters.
- Deleveraging path is tied to project loan schedules: Project loans generally carry a one-year post-completion moratorium followed by seven years of repayment; terms vary loan to loan. Management stated cash flow is comfortable.
- CMCD will eventually self-fund: After FY27, the CMCD business is expected to generate enough operating cash flow to cover all future capex, somewhere in the FY27–28 period.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CMCD revenue | ₹1,000 crores | By FY27 |
| CMCD EBITDA margin | 20–25% | At maturity (currently slightly lower) |
| CMCD self-sustaining cash flow | Fund all future capex from operating cash flow | FY27–28 period |
| R32 swing plant (first 2 kt) | Operational, converting existing R22 plant | By 1 January |
| R32 second 2 kt plant | Operational | By ~April |
| R32 10 kt plant decision | Capex decision | Before end-December |
| R32 quota allocation rules | Full clarity | ~Calendar 2027 |
| Paste PVC ADD petition against EU | New anti-dumping petition | Underway, no timeline given |
| Suspension PVC ADD | If not implemented, 2–3 quarters of challenge | Starting from lapse date |
| CMCD molecule ramp-up | Deferment of newly launched molecules | A couple of quarters |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹1,033 cr, marginal increase from ₹993 cr in Q2 FY25 |
| EBITDA | ₹43 cr, up from ₹26 cr in Q2 FY25 and ₹17 cr in Q1 FY26 |
| Net loss | ₹51 cr, compared to a net loss of ₹115 cr in H1 FY26 |
| Specialty Chemicals segment revenue | ₹372 cr, 22% YoY growth from ₹306 cr |
| Value-added Chemicals segment revenue | ₹138 cr, 12% YoY decline |
| Suspension PVC business revenue | ₹523 cr, flat YoY |
| Value-added chemicals volumes | -15% YoY |
| Suspension PVC sales volume | +11% YoY |
| Paste PVC capacity | ~110,000 tonnes |
| Standalone business EBITDA | ₹18 cr |
| Net debt | ₹1,300 cr |
| CMCD products commercialized | 17 products, with 3 commercialized this year and one more anticipated in Q4 |
| CMCD revenue guidance | ₹1,000 cr by FY27 |
| CMCD EBITDA margin target | 20% to 25% |
| Chinese Suspension PVC price | $650, with VCM at around $500 |